Therapeutic benefits of S. boulardii CNCM I-745 are backed with strong clinical and scientific evidence

The single-strain yeast probiotic Saccharomyces boulardii CNCM I-745 is indicated for the prevention and treatment of diarrhea in adults and children.¹ These recommendations are based on both non-clinical investigations and high quality robust clinical studies.²

Saccharomyces boulardii CNCM I-745 has strong clinical evidence leading to multiple recommendations as a treatment and prevention for diarrhea

The efficacy of S. boulardii CNCM I-745 to prevent and treat diarrhea has been demonstrated in numerous clinical studies investigating diarrhea due to causes including infectious diarrhea and antibiotic treatments in both adults and children.²

These clinical findings have led to the classification of S. boulardii CNCM I-745 as a probiotic drug^2,*, which means that this probiotic is backed by strong, good quality clinical evidence, as well as meeting the strict manufacturing requirements for a biological drug classification.²

The wealth of clinical evidence of the multiple proven health benefits of S. boulardii CNCM I-745 supports its use for gastrointestinal disorders including :

• management and prevention of acute diarrhea¹ ;
• prevention of antibiotic-associated diarrhea¹ ;
• prevention of recurrent Clostridium difficile infections following antibiotic treatment¹ ;
• prevention of Helicobacter pylori eradication treatment-associated side effects.¹

Furthermore, because of the strong non-clinical and clinical evidence that has been generated with S. boulardii CNCM I-745, the health benefits and use of this yeast probiotic drug in both adults and children are endorsed by multiple scientific societies, including:

• The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)^5,6 ;
• The World Gastroenterology Organisation⁷ ;
• Recommendations for probiotics in paediatric and adult gastrointestinal disease in the Asia-Pacific Region^8,9 ;
• Recommendations of the Latin-American expert consensus group for the use of probiotics in paediatric gastroenterology¹⁰ ;
• Maastricht V/Florence Consensus Report for the management of H. pylori.¹¹

*In the majority of countries where S. boulardii CNCM I-745 is available.

Saccharomyces boulardii CNCM I-745 multiple specific mechanisms of action to address diarrhea and restore microbiota balance

Non-clinical scientific studies have investigated and demonstrated that S. boulardii CNCM I-745 has multiple, specific mechanisms of action against the causes and symptoms of diarrhea and intestinal dysbiosis including:

1. Anti-microbial activity
   • Produces 3 proteins that target the toxins produced by pathogenic bacteria³ ;
   • Binds pathogenic bacteria and strengthens tight junctions to prevent invasion³ ;
2. Anti-inflammatory activity² ;
   • Reduces the production of anti-inflammatory cytokines² ;
3. Immune stimulation² ;
   • S. boulardii CNCM I-745 stimulates the production of secreted immunoglobulin A that targets pathogenic microbes.²
4. Positive effects on gut function² ;
   • Stimulates production of short-chain fatty acids
   • that increase fluid absorption²
   • Produces polyamines, substances involved in maintaining healthy enterocytes.²
5. Restoration of gut microbiota composition and diversity.⁴
   • Through its multiple mechanisms of action, S. boulardii CNCM I-745 has been demonstrated to rapidly restore the composition and diversity of beneficial microbiota⁴ that contribute to normal gut functioning such as fermentation and the metabolism of nutrients.⁴
     • In part by preventing the overgrowth of pathogens that outcompete with the microbiota, and also creating a positive growth environment for the microbiota.⁴

In particular, specific mechanisms of action against potentially dangerous pathogens that cause diarrhea³ has been demonstrated, where the yeast :

• Destroys the toxins produced by Clostridium difficile, Cholera toxin, as well as the toxic lipopolysaccharide of Escherichia coli³ ;
• Binding to invasive pathogens such as Salmonella typhimurium and increasing its elimination from the gut³ ;
• Produces capric acidthat inhibits Candida albicans virulence².